2Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan [J]. Ann Oncol, 1997,8(suppl1 ): 107-109.
3Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B carriers with hematological malignancies [ J ]. Cancer, 1996,78 (10): 2210-2215.
4Liang RH, Lok AS, Lai CL, et al. Hepatitis B infection in patients with lymphomas [J]. Hematol Oncol, 1990,8(5):261-270.
5Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors [J]. J Med Virol, 2000,62(3):299-307.
6Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy.Report of a prospective study [J]. Gastroenterology, 1991,100( 1 ): 182-188.
7Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem [J]. JCO, 1999,17( 1 ): 394-398.
8Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undegoing cytotoxic chemotherapy[J]. JCO, 2004,22(5) :927-934.
9Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virusinfected patients treated for non-Hodgkin lymphoma [J].Blood, 2002,99(2) :724-725.
